UCI Comprehensive Cancer Center

Updates in CLL from #ASH24 Has SOC changed?

Elizabeth Brem, MD Associate Clinical Professor


www.cancer.uci.edu

Disclosures

- Speakers Bureau: AstraZeneca, AbbVie/Genmab, BMS
- Advisory Boards: BeiGene, AstraZeneca, ADC Therapeutics, Caribou Biosciences, Poseida
- Consulting: Caribou Biosciences, Regeneron, Genetech, Incyte
- Promotional Services Provided: AstraZeneca


Ibrutinib + Venetoclax

2021-2023: CAPTIVATE (fixed-duration)



Tam CS et al, Blood, 2023. ⁴

CAPTIVATE: High Risk






Allan JN et al, Cancer Res, 2023.


2021-2023: FLAIR


*updated at ASH: abstract 585



UCI &Chao Family Comprehensive Cancer Center Munir T et al, NEJM, 2023 6

2021-2023: FLAIR (PFS)






Patients with Mutated IGHV

Munir T et al, NEJM, 2023 7

2021-2023: FLAIR (OS)



UCI & Chao Family Comprehensive Cancer Center

Munir T et al, NEJM, 2023 ⁸

NCCN v1.2025

	SUGGESTED TREATMENT REGIME CLL/SLL Without del(17p)/ <i>TP53</i> Mu (alphabetical by category)	
	FIRST-LINE THERAPY ^e	-Toring the last of the last o
Preferred Regimens	Other Recommended Regimens	Useful in Certain Circumstances
 • cBTKi ▶ Acalabrutinib^{f,g,*} ± obinutuzumab (category 1) ▶ Zanubrutinib^{f,g,*} (category 1) • Venetoclax^{f,h} + obinutuzumab (category 1) 	• cBTKi ▶ Ibrutinib ^{f,g,i,*} (category 1) • Ibrutinib ^{f,g,*} + venetoclax ^{f,h}	 Consider for IGHV-mutated CLL in patients aged <65 y without significant comorbidities FCR (fludarabine, cyclophosphamide, rituximab)^{j,k} Ibrutinib^{f,g,*} + anti-CD20 mAb (category 2B)^l Consider when cBTKi and venetoclax are not available or contraindicated or rapid disease debulking needed Bendamustine^m + anti-CD20 mAb^{l,n} Obinutuzumab ± chlorambucil^o High-dose methylprednisolone (HDMP) + anti-CD20 mAb^l (category 2B; category 3 for patients <65 y without significant comorbidities)

* Covalent BTKi (cBTKi).

NCCN v1.2025

SUGGESTED TREATMENT REGIMENS^{a,b,c,d} CLL/SLL With del(17p)/TP53 Mutation (alphabetical by category) CIT is not recommended since del(17p)/TP53 mutation is associated with low response rates.


FIRST-LINE THERAPY ^e			
Preferred Regimens	Other Recommended Regimens	Useful in Certain Circumstances	
 • cBTKi ▶ Acalabrutinib^{f,g} ± obinutuzumab ▶ Zanubrutinib^{f,g} • Venetoclax^{f,h} + obinutuzumab 	• cBTKi ▶ Ibrutinib ^{f,g,i} • Ibrutinib ^{f,g,*} + venetoclax ^{f,h}	 Consider when cBTKi and venetoclax are not available or contraindicated or rapid disease debulking needed HDMP + anti-CD20 mAb¹ Obinutuzumab 	

Why didn't I+V become widely adopted?

- •**no FDA approval
- General movement away from ibrutinib
- Comfort with ongoing cBTKi
 Especially for high risk features
 Fear of ven?
- Confusion studies varied in terms of duration of therapy, MRD assays used, etc



Triple vs Doublet




Undetectable Minimal Residual Disease at 15 Mo



Eichhorst B et al, NEJM, 2023

Does MRD negativity translate to PFS?



UCI Chao Family Comprehensive Cancer Center Eichhorst B et al, NEJM, 2023

2024-2025: AMPLIFY

Abstract 1009

AMPLIFY Study Design

TN CLL (N=867)

Key inclusion criteria


- Age ≥18 years
- TN CLL requiring treatment per iwCLL 2018 criteria¹
- Without del(17p) or TP53^a
- ECOG PS ≤2

Key exclusion criteria

- CIRS-Geriatric >6
- Significant cardiovascular disease

Stratification

- Age (>65 vs ≤65 years)
- IGHV mutational status
- Rai stage (≥3 vs <3)
- Geographic region



AV, acalabrutinib-venetoclax; AVO, acalabrutinib-venetoclax-obinutuzumab; BR, bendamustine-rituximab; CIRS-Geriatric; Cumulative Illness Rating Scale-Geriatric; CLL, chronic lymphocytic leukemia; ECOG PS, Eastern Cooperative Oncology Group performance status; FCR, fludarabine-cyclophosphamide-rituximab; IGHV, immunoglobulin heavy-chain variable region gene; iwCLL, International Working Group on CLL; OS, overall survival; PFS, progression-free survival; TN, treatment-naive;

uMRD, undetectable measurable residual disease.
 Hallek M, et al. *Blood*. 2018;131:2745-60.

NCT03836261. Data cutoff: April 30, 2024.

^aAssayed by central lab.


Brown JR et al, 2024 ASH Annual Meeting ¹⁵

AMPLIFY: randomized, multicenter, open-label, Ph 3 trial

Demographics and Baseline Characteristics

Characteristic	AV (n=291)	AVO (n=286)	FCR/BR (n=290)
Age, median (range), yr	61 (31–84)	61 (29–81)	61 (26-86)
≤65 yr	212 (72.9)	210 (73.4)	213 (73.4)
>65 yr	79 (27.1)	76 (26.6)	77 (26.6)
Male sex	178 (61.2)	198 (69.2)	183 (63.1)
ECOG PS score			
0–1	262 (90.0)	272 (95.1)	262 (90.3)
2	28 (9.6)	14 (4.9)	26 (9.0)
Geographic region*			
Europe	184 (63.2)	179 (62.6)	183 (63.1)
North America	50 (17.2)	51 (17.8)	50 (17.2)
Other	57 (19.6)	56 (19.6)	57 (19.7)
Rai stage			
0-11	154 (52.9)	170 (59.4)	163 (56.2)
III–IV	137 (47.1)	116 (40.6)	127 (43.8)
del(11q) present	51 (17.5)	56 (19.6)	46 (15.9)
Unmutated IGHV	167 (57.4)	169 (59.1)	172 (59.3)
Complex karyotype (≥3 aberrations)	45 (15.5)	46 (16.1)	42 (14.5)

IRC-assessed PFS




Median PFS was NR for AV and AVO, and was 47.6 mo for FCR/BR



Brown JR et al, 2024 ASH Annual Meeting ¹⁷


PFS in the uIGHV Subgroup




UCI &Chao Family Comprehensive Cancer Center

Brown JR et al, 2024 ASH Annual Meeting ¹⁸

PFS in the mIGHV Subgroup




PFS Censoring COVID-19 Deaths (Prespecified Analysis)



Brown JR et al, 2024 ASH Annual Meeting ²⁰

uMRD Rates (Flow Cytometry [<10-4] in PB)




Key secondary endpoint timing: cycle 9, day 1 (AV arm), cycle 10, day 1 (AVO arm), and cycle 6, day 1 plus 12 weeks (FCR/BR)

UCI Comprehensive Cancer Center


Brown JR et al, 2024 ASH Annual Meeting ²¹

PFS in the uMRD Subgroup at EOT (Flow Cytometry [<10⁻⁴] in PB)



Brown JR et al, 2024 ASH Annual Meeting ²²


PFS in the MRD+ Subgroup at EOT (Flow Cytometry [<10⁻⁴] in PB)



Overall Survival

OS Prolonged With AV vs FCR/BR

OS Prolonged With AV and AVO vs FCR/BR (COVID-19 Deaths Censored)



COVID-19 deaths: 10 (AV), 25 (AVO), 21 (FCR/BR)

Brown JR et al, 2024 ASH Annual Meeting ²⁴



Safety Summary

	AV (n=291)	AVO (n=284)	FCR/BR (n=259)
Duration of exposure, median (range), mo	12.9 (1–18)	12.9 (0–18)	5.6 (1–11)
Summary of AEs			
Any AE	270 (92.8)	269 (94.7)	236 (91.1)
Any AE grade ≥3	156 (53.6)	197 (69.4)	157 (60.6)
Any serious AE	72 (24.7)	109 (38.4)	71 (27.4)
Serious AEs leading to death	10 (3.4)	17 (6.0)	9 (3.5)
AE leading to treatment discontinuation	23 (7.9)	57 (20.1)	28 (10.8)



Brown JR et al, 2024 ASH Annual Meeting ²⁵


When might we chose AVO over AV?

- Patient willing to risk more viral infections in exchange for higher likelihood of MRD negativity?
- uIGVH?




What about AVO in higher risk groups?

Phase 2: AVO in pts with TP53 aberration




MRD at C16 & C25 assessed by multicolor flow cytometry (10⁻⁴)

Phase 2: AVO in pts with TP53 aberration




Phase 2: AVO in pts with TP53 aberration




UCI &Chao Family Comprehensive Cancer Center MRD via ClonoSeq

Davids MS et al, JCO, 2024 ³⁰

PFS: AVO in pts with TP53 aberration



OS: AVO in pts with TP53 aberration



Safety

AE	Any Grade, No. of Patients (%)	Grade ≥3, No. of Patients (%)	
Any AE	71 (99)	40 (56)	
Any SAE	19 (26)	17 (24)	
Common AEs (≥25% of patients)			
Fatigue	59 (82)	2 (3)	
Headache	54 (75)	1 (1)	
Neutropenia	52 (72)	26 (36)	
Thrombocytopenia	51 (71)	20 (28)	
Bruising	47 (65)	0	
Anemia	37 (51)	3 (4)	
Nausea	37 (51)	0	
Diarrhea	34 (47)	4 (6)	
Hypocalcemia	31 (43)	1 (1)	

Davids MS et al, JCO, 2024 ³³

Safety

	AE	Any Grade, No. of Patients (%)	Grade ≥3, No. of Patients (%)
	Rash maculopapular	18 (25)	0
	AEs of special interest		
	Infection ^a	33 (46)	7 (10)
	Hypertension	8 (11)	7 (10)
	Infusion-related reactions	20 (28)	3 (4)
	Bleeding events	8 (11)	0
	Neoplasms benign, malignant, and unspecified (including cysts and polyps)	8 (11)	4 (6)
	Atrial fibrillation	4 (6)	2 (3)
	Tumor lysis syndrome	3 (4)	3 (4)
	Ventricular arrhythmias	0 (0)	0 (0)

What questions remain?


- How much does the O add in the population with TP53 aberration?
 This study had fewer COVID deaths than AMPLIFY
- What about other high risk features?
 - Complex karyotype?
- Role for re-treatment?
 - Looking to balance PFS with toxicity for higher-risk patients

Sonrotoclax + zanubrutinib Abstract 1012

BGB-11417-101 (NCT04277637) Study Design

BGB-11417-101: TN CLL

- BGB-11417-101 is a global phase 1/1b study evaluating sonrotoclax as monotherapy, or in combination with zanubrutinib and/or obinutuzumab in patients with B-cell malignancies
- The study endpoints included safety per CTCAE v5.0, RP2D, and efficacy
- Treatment consisted of 8-12 weeks of zanubrutinib lead-in (320 mg QD or 160 mg BID), then zanubrutinib + sonrotoclax until disease progression or intolerance



BID=twice daily, CLL=chronic lymphocytic leukemia, CTCAE=Common Terminology Criteria for Adverse Events, MCL=mantle cell lymphoma, QD=once daily, RP2D=recommended phase 2 dose, R/R=relapsed/refractory, SLL=small lymphocytic lymphoma, TN=treatment naïve.

Baseline Characteristics

BGB-11417-101: TN CLL

Characteristics	Sonro 160 mg + zanu (n=51)	Sonro 320 mg + zanu []](n=86)	All Patients (N=137)
Study follow-up, median (range), months	19.5 (12.6-33.3)	19.3 (0.4-29.7)	19.4 (0.4-33.3)
Age, median (range), years	63 (38-82)	61 (32-84)	62 (32-84)
≥65 years, n (%)	20 (39.2)	35 (40.7)	55 (40.1)
Male sex, n (%)	37 (72.5)	61 (70.9)	98 (71.5)
Disease type, n (%)			
CLL	48 (94.1)	82 (95.3)	130 (94.9)
SLL	3 (5.9)	4 (4.7)	7 (5.1)
Risk status, n/tested (%)			
del(17p)	5/45 (11.1)	6/77 (7.8)	11/122 (9.0)
TP53 mutation ^a	11/47 (23.4)	13/62 (21.0)	24/109 (22.0)
del(11q)	10/45 (22.2)	11/77 (14.3)	21/122 (17.2)
IGHV status, n/tested (%)			
Unmutated IGHV	32/47 (68.1)	32/60 (53.3)	64/107 (59.8)
High tumor bulk ^b at baseline, n/tested (%)	22/51 (43.1)	17/82 (20.7)	39/133 (29.3)

Data cutoff: August 23, 2024.


aTP53 mutations defined as >0.1% VAF. bNodes ≥10 cm or nodes >5 cm and ALC >25×10⁹/L.

ALC=absolute lymphocyte count, CLL=chronic lymphocytic leukemia, IGHV=immunoglobulin heavy chain variable region, SLL=small lymphocytic lymphoma, VAF=variant allele frequency.

TEAEs Observed With Sonrotoclax + Zanubrutinib Were Mostly Low Grade and Transient

BGB-11417-101: TN CLL

- No TLS
- Neutropenia was transient and did not lead to higher rates of grade ≥3 infections




TEAEs in ≥10% of all patients

Patients, %

Sonrotoclax + Zanubrutinib Demonstrates Antitumor Activity in TN CLL

BGB-11417-101: TN CLL




^aPercentages based on the number of patients who reached assessment at 24 or 48 weeks after completion of ramp-up, following zanu monotherapy and sonro ramp-up to target dose. CR=complete response, CRi=complete response with incomplete count recovery, PR, partial response, SD=stable disease.

High Blood uMRD4 Rates Occurred Early and All Patients Remain in uMRD

BGB-11417-101: TN CLL

• As of the data cutoff date, no patients had switched from uMRD to MRD4+




^aAs measured by ERIC flow cytometry panel; uMRD4 is defined as less than 1 CLL cell per 10,000 leukocytes (<10⁻⁴). ^bNumber of weeks at target dose, following zanu monotherapy and sonro ramp-up to target dose. CLL=chronic lymphocytic leukemia. ERIC=European Research Initiative in CLL. MRD=minimal residual disease. uMRD=undetectable minimal residual disease.

At Median Study Follow-Up of 19.4 Months, No Progression Was Observed With Sonrotoclax 320 mg

BGB-11417-101: TN CLL

• 1 PFS event in sonrotoclax 160-mg cohort (Richter transformation)



What else happened at ASH in CLL?

Not yet ready for prime time...

- Ibrutinib + liso-cel (abstract 887)
 - CR better than lisp-cel alone (45% vs 20%), but CART use likely to remain rare in CLL
- BRUIN CLL-321: pirto vs ideal/BR (abstract 886)
 - Not a useful comparator arm
- BTK degraders looking good
 - Mostly PRs, but durable



Questions?

ebrem@hs.uci.edu

X @DrLizBrem

